Latanoprost TOA Ophthalmic Solution 0.005% w/v

Latanoprost TOA Ophthalmic Solution 0.005% w/v

latanoprost

Manufacturer:

Nitto Medic

Distributor:

Pharmaforte
Full Prescribing Info
Contents
Latanoprost.
Description
A clear, colorless liquid.
Composition and description: (See Table 1.)

Click on icon to see table/diagram/image
Action
Pharmacotherapeutic Group: Prostaglandin F2a analogue. Glaucoma and ocular hypertension treatment agent.
Pharmacology: Pharmacodynamics: The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist that reduces the IOP by increasing the outflow of aqueous humor, primarily through the uveoscleral route and also through the trabecular meshwork. Reduction of the intraocular pressure in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours. Pressure reduction is maintained for at least 24 hours. Pivotal studies have demonstrated that Xalatan is effective as a monotherapy. In addition clinical trials investigating combination use have been performed. These include studies that show that latanoprost is effective in combination with beta-adrenergic antagonists (timolol). Short term (1 or 2 weeks) studies suggest that the effect of latanoprost is additive in combination with adrenergic agonists (dipivalyl epinephrine, oral carbonic anhydrase inhibitors (acetazolamide) and at least partly additive with cholinergic agonists (pilocarpine).
Clinical trials have shown that latanoprost has no significant effect on the production of aqueous humor. Latanoprost has not been found to have any effect on the blood-aqueous barrier.
Clinical studies of latanoprost in primary chronic angle closure glaucoma have been limited to 12 weeks. Clinical efficacy and safety in patients with primary chronic angle glaucoma have not been established beyond 12 weeks.
Latanoprost has not induced fluorescein leakage in the posterior segment of pseudophakic human eyes during short-term treatment.
Latanoprost in clinical doses has not been found to have any significant pharmacological effects on the cardiovascular or respiratory system.
Pharmacokinetics: Absorption: Latanoprost is absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form to become biologically active. Studies in man indicate that the peak concentration in the aqueous humor is reached about two hours after topical administration.
Distribution: The distribution volume in humans is 0.16 ± 0.02 L/kg. The acid of latanoprost can be measured in aqueous humor during the first four hours, and in plasma only during the first hour after local administration.
Metabolism: Latanoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to the biologically active acid. The active acid of latanoprost reaching the systemic circulation is primarily metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites via fatty acid β-oxidation.
Excretion: The elimination of the acid of latanoprost from human plasma is rapid (t1/2=17 min) after both intravenous and topical administration. Systemic clearance is approximately 7 mL/min/kg. Following hepatic β-oxidation, the metabolites are mainly eliminated via the kidneys. Approximately 88% and 98% of the administered dose is recovered in the urine after topical and intravenous dosing, respectively.
Toxicology: Preclinical safety data: Systemic/Ocular Effects: The ocular as well as systemic toxicity of latanoprost has been investigated in several animal species. Generally, latanoprost is well tolerated with a safety margin between clinical ocular dose and systemic toxicity of at least 1000 times. High doses of latanoprost, approximately 100 times the clinical dose/kg body weight, administered intravenously to unanesthetized monkeys have been shown to increase the respiration rate probably reflecting bronchoconstriction of short duration. In monkeys, latanoprost has been infused intravenously in doses of up to 500 mcg/kg without major effects on the cardiovascular system. In animal studies, latanoprost has not been found to have sensitizing properties. In the eye, no toxic effects have been detected with doses of up to 100 micrograms/eye/day in rabbits or monkeys (clinical dose is approximately 1.5 micrograms/eye/day). Latanoprost has no or negligible effects on the intraocular blood circulation when used at the clinical dose and studied in monkeys.
In chronic ocular toxicity studies, administration of latanoprost 6 micrograms/eye/day has also been shown to induce increased palpebral fissure. This effect is reversible and occurs at doses above the clinical dose level. The effect has not been seen in humans.
Carcinogenesis: Carcinogenicity studies in mice and rats were negative.
Mutagenesis: Latanoprost was found negative in reverse mutation tests in bacteria, gene mutation in mouse lymphoma and mouse micronucleus test. Chromosome aberrations were observed in vitro with human lymphocytes. Similar effects were observed with prostaglandin F2α, a naturally occurring prostaglandin, and indicate that this is a class effect.
Additional mutagenicity studies on in vitro/in vivo unscheduled DNA synthesis in rats were negative and indicate that latanoprost does not have mutagenic potency.
Impairment of Fertility: Latanoprost has not been found to have any effect on male or female fertility in animal studies. In the embryotoxicity study in rats, no embryotoxicity was observed at intravenous doses (5, 50 and 250 micrograms/kg/day) of latanoprost. However, latanoprost induced embryolethal effects in rabbits at doses of 5 micrograms/kg/day and above. Latanoprost has been shown to cause embryofetal toxicity in rabbits characterized by increased incidences of late resorption and abortion and reduced fetal weight when given in intravenous doses approximately 100 times the human dose.
Teratogenesis: No teratogenic potential has been detected.
Indications/Uses
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. It may also be used for the reduction of elevated intraocular pressure as an adjunct medical therapy in patients with primary chronic angle closure glaucoma.
Dosage/Direction for Use
One drop in the affected eye(s) once daily. Optimal effect is obtained if latanoprost is administered in the evening.
The dosage of latanoprost should not exceed once daily since it has been shown that more frequent administration decreases the intraocular pressure lowering effect.
If one dose is missed, treatment should continue with the next dose as normal.
Patients should be instructed the following: Instill the product with care not to touch the eye with the dropper tip.
If the solution exceeds to the eyelid skin during instilling the product, wipe off any excess solution immediately.
If this product is used with other ophthalmic solution, they should be administered at least 5 minutes apart.
Since this product contains benzalkonium chloride and it may discolor contact lenses, contact lenses should be removed before instillation of the product and should be inserted again after 15 minutes or more.
Overdosage
If overdosage with latanoprost occurs, treatment should be symptomatic.
Contraindications
Known hypersensitivity to latanoprost or any other component of the product.
Special Precautions
Careful Administration: (This product should be administered with special caution in the following patients.)
Aphakic patients, pseudophakic patients with a torn posterior lens capsule. (Macular edema, including cystoid macular edema and the decreased visual acuity associated with macular edema, have been reported.)
There is no experience in patients with severe or brittle asthma. Such patients should therefore be treated with caution until there is sufficient experience.
Patients with intraocular inflammation (iritis/uveitis).
Important Precautions: When this product is administered, the iris pigmentation may occur (due to increased melanin content). Before using this product, patients who receive treatment should be well informed of the possibility of the iris pigmentation and the change in iris color. It is reported that pigmentation is expected to increase gradually and stops after discontinuation of treatment. However, the resultant pigmentation is likely to be permanent.
In addition, iris color change due to the iris pigmentation may occur. In particular, the treatment of one eye may cause iris color difference between the right and left eyes.
This product should be administered with special caution in the patients with angle-closure glaucoma due to an insufficient clinical experience.
Benzalkonium chloride has been reported to cause eye irritation, dry eyes and may affect the corneal surface. Latanoprost "TOA" Ophthalmic Solution 0.005% should be used with caution in dry eye patients and in patients where the cornea may be compromised. In addition, monitoring is required with prolonged use in such patients.
Effects on ability to drive and use machines: Since blurred vision may temporarily occur after administration of the product, patients should be advised to refrain from operating machinery or driving a car until the symptoms recover.
Use in Children: The safety of this product in pediatric patients has not been established. (No clinical data are available for premature infants, newborns, and infants. Very limited clinical data are available for children.)
Use In Pregnancy & Lactation
Fertility: Latanoprost has not been found to have any effect on male or female fertility in animal studies.
Pregnancy: This product should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. (The safety of this product during pregnancy has not been established. Reproduction studies have been performed in rabbits. In the study of administration during organogenesis in rabbits, it has been shown that increased incidences of late resorption ad abortion and reduced fetal weight when given in intravenous doses approximately 100 times the recommended clinical dose [5.0 μg/kg/day]).
Lactation: Administration of this product should be avoided to a nursing woman. If treatment with this product becomes essential, breast feeding must be discontinued. (An animal study [in rats, i.v.] has shown that the drug was excreted in breast milk.)
Adverse Reactions
(See Table 2.)

Click on icon to see table/diagram/image
Drug Interactions
Precautions for co-administration: (See Table 3.)

Click on icon to see table/diagram/image
Storage
Protect from light and store at room temperature (1-30°C).
Shelf life: Indicated on the package and label (2 years).
Shelf life after opening: 4 weeks when stored at or below 30°C.
ATC Classification
S01EE01 - latanoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.
Presentation/Packing
Ophth soln 0.005% w/v x 2.5 mL x 10's.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in